OrbitonOpen research workspace →
Atyr Pharma Inc. logo

Atyr Pharma Inc.

NASDAQ:ATYRLive AI agent

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.

Investor website: https://atyrpharma.com/

About

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Their lead therapeutic candidate, efzofitimod, is in clinical development for interstitial lung disease (ILD), targeting immune-mediated disorders that cause chronic inflammation and fibrosis of the lungs. The company is focused on unlocking therapeutic intervention points through its proprietary library of tRNA synthetase-derived domains.

Verified company data

Cash position
$92.9 million
Shares outstanding
53,162,052
Projects
["Efzofitimod is a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. We are currently investigating efzofitimod in pulmonary sarcoidosis, a major form of ILD, and systemic sclerosis (SSc, or scleroderma)-related ILD. We recently reported results from the Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis, and the Phase 2 EFZO-CONNECT™ study of efzofitimod in patients with SSc-ILD is ongoing."]
Leadership
Sanjay S. Shukla, M.D., M.S. (President and CEO, Director), Jill M. Broadfoot (Chief Financial Officer), Nancy E. Denyes (General Counsel), Andrea Cubitt, Ph.D. (VP, External Scientific Alliances & Intellectual Property), Peter Villiger (VP, Corporate Development), Leslie Nangle, Ph.D. (VP, Research), Robert W. Ashworth, Ph.D. (VP, Regulatory Affairs), Danielle Campbell (VP, Human Resources), Lisa Carey (VP, Clinical Operations), Dalia R. Rayes (Head of Commercial, Global Efzofitimod Franchise), Darin Lee, Ph.D. (VP, Technical Operations), Brandon Yaras (Vice President, Finance), Timothy P. Coughlin (Chairman), Jane A. Gross, Ph.D. (Director), Svetlana Lucas, Ph.D. (Director), Sanjay S. Shukla, M.D., M.S. (Director), Sara L. Zaknoen, M.D. (Director), Eric Benevich (Director)

Verified data last updated:

Recent filings